nodes	percent_of_prediction	percent_of_DWPC	metapath
Azilsartan medoxomil—Losartan—type 2 diabetes mellitus	0.38	1	CrCtD
Azilsartan medoxomil—AGTR1—Valsartan—type 2 diabetes mellitus	0.103	0.406	CbGbCtD
Azilsartan medoxomil—AGTR1—Irbesartan—type 2 diabetes mellitus	0.0916	0.361	CbGbCtD
Azilsartan medoxomil—AGTR1—Losartan—type 2 diabetes mellitus	0.059	0.233	CbGbCtD
Azilsartan medoxomil—Tasosartan—Irbesartan—type 2 diabetes mellitus	0.0323	0.108	CrCrCtD
Azilsartan medoxomil—Telmisartan—Losartan—type 2 diabetes mellitus	0.0306	0.102	CrCrCtD
Azilsartan medoxomil—Olmesartan—Irbesartan—type 2 diabetes mellitus	0.029	0.0968	CrCrCtD
Azilsartan medoxomil—Tasosartan—Valsartan—type 2 diabetes mellitus	0.0275	0.0916	CrCrCtD
Azilsartan medoxomil—Losartan—Irbesartan—type 2 diabetes mellitus	0.0264	0.0881	CrCrCtD
Azilsartan medoxomil—Olmesartan—Valsartan—type 2 diabetes mellitus	0.0247	0.0823	CrCrCtD
Azilsartan medoxomil—Candesartan—Irbesartan—type 2 diabetes mellitus	0.0243	0.081	CrCrCtD
Azilsartan medoxomil—Tasosartan—Losartan—type 2 diabetes mellitus	0.0234	0.0779	CrCrCtD
Azilsartan medoxomil—Losartan—Valsartan—type 2 diabetes mellitus	0.0225	0.0749	CrCrCtD
Azilsartan medoxomil—Olmesartan—Losartan—type 2 diabetes mellitus	0.021	0.07	CrCrCtD
Azilsartan medoxomil—Candesartan—Valsartan—type 2 diabetes mellitus	0.0207	0.0689	CrCrCtD
Azilsartan medoxomil—Candesartan—Losartan—type 2 diabetes mellitus	0.0176	0.0586	CrCrCtD
Azilsartan medoxomil—AGTR1—artery—type 2 diabetes mellitus	0.00155	0.265	CbGeAlD
Azilsartan medoxomil—AGTR1—endothelium—type 2 diabetes mellitus	0.00131	0.224	CbGeAlD
Azilsartan medoxomil—Tasosartan—AGTR2—type 2 diabetes mellitus	0.000999	0.542	CrCbGaD
Azilsartan medoxomil—AGTR1—nephron tubule—type 2 diabetes mellitus	0.0006	0.103	CbGeAlD
Azilsartan medoxomil—AGTR1—cardiovascular system—type 2 diabetes mellitus	0.000539	0.0921	CbGeAlD
Azilsartan medoxomil—AGTR1—kidney—type 2 diabetes mellitus	0.000527	0.0902	CbGeAlD
Azilsartan medoxomil—AGTR1—cortex of kidney—type 2 diabetes mellitus	0.000513	0.0878	CbGeAlD
Azilsartan medoxomil—AGTR1—adipose tissue—type 2 diabetes mellitus	0.000475	0.0813	CbGeAlD
Azilsartan medoxomil—Blood creatinine increased—Sitagliptin—type 2 diabetes mellitus	0.00037	0.00887	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Repaglinide—type 2 diabetes mellitus	0.00035	0.00838	CcSEcCtD
Azilsartan medoxomil—Angioedema—Linagliptin—type 2 diabetes mellitus	0.000349	0.00835	CcSEcCtD
Azilsartan medoxomil—Hyperuricaemia—Irbesartan—type 2 diabetes mellitus	0.000344	0.00824	CcSEcCtD
Azilsartan medoxomil—AGTR1—liver—type 2 diabetes mellitus	0.000333	0.057	CbGeAlD
Azilsartan medoxomil—Gastrointestinal disorder—Miglitol—type 2 diabetes mellitus	0.000332	0.00795	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Rosiglitazone—type 2 diabetes mellitus	0.000331	0.00792	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Rosiglitazone—type 2 diabetes mellitus	0.00033	0.0079	CcSEcCtD
Azilsartan medoxomil—Blood uric acid increased—Irbesartan—type 2 diabetes mellitus	0.000325	0.00779	CcSEcCtD
Azilsartan medoxomil—Hyperuricaemia—Losartan—type 2 diabetes mellitus	0.000324	0.00776	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Linagliptin—type 2 diabetes mellitus	0.000323	0.00773	CcSEcCtD
Azilsartan medoxomil—Blood uric acid increased—Losartan—type 2 diabetes mellitus	0.000306	0.00733	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Linagliptin—type 2 diabetes mellitus	0.000303	0.00724	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Tolbutamide—type 2 diabetes mellitus	0.000299	0.00715	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Pioglitazone—type 2 diabetes mellitus	0.000277	0.00664	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Pioglitazone—type 2 diabetes mellitus	0.000277	0.00662	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Chlorpropamide—type 2 diabetes mellitus	0.000272	0.00651	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Tolazamide—type 2 diabetes mellitus	0.000272	0.00651	CcSEcCtD
Azilsartan medoxomil—Fatigue—Tolazamide—type 2 diabetes mellitus	0.000271	0.0065	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Sitagliptin—type 2 diabetes mellitus	0.000269	0.00645	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Linagliptin—type 2 diabetes mellitus	0.000269	0.00644	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Sitagliptin—type 2 diabetes mellitus	0.000269	0.00643	CcSEcCtD
Azilsartan medoxomil—Angioedema—Rosiglitazone—type 2 diabetes mellitus	0.000267	0.00639	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Miglitol—type 2 diabetes mellitus	0.000263	0.0063	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Repaglinide—type 2 diabetes mellitus	0.000262	0.00626	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Acarbose—type 2 diabetes mellitus	0.000261	0.00625	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Valsartan—type 2 diabetes mellitus	0.000253	0.00605	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Nateglinide—type 2 diabetes mellitus	0.000252	0.00603	CcSEcCtD
Azilsartan medoxomil—Fatigue—Nateglinide—type 2 diabetes mellitus	0.000251	0.00602	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Sitagliptin—type 2 diabetes mellitus	0.000248	0.00594	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Glipizide—type 2 diabetes mellitus	0.000246	0.00589	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Repaglinide—type 2 diabetes mellitus	0.000245	0.00587	CcSEcCtD
Azilsartan medoxomil—Pruritus—Tolbutamide—type 2 diabetes mellitus	0.000245	0.00586	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Bromocriptine—type 2 diabetes mellitus	0.000244	0.00584	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Bromocriptine—type 2 diabetes mellitus	0.000243	0.00582	CcSEcCtD
Azilsartan medoxomil—Rash—Miglitol—type 2 diabetes mellitus	0.000243	0.00581	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Miglitol—type 2 diabetes mellitus	0.000242	0.0058	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Pioglitazone—type 2 diabetes mellitus	0.000236	0.00564	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Rosiglitazone—type 2 diabetes mellitus	0.000234	0.0056	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Sitagliptin—type 2 diabetes mellitus	0.000229	0.00548	CcSEcCtD
Azilsartan medoxomil—Nausea—Miglitol—type 2 diabetes mellitus	0.000229	0.00547	CcSEcCtD
Azilsartan medoxomil—Asthenia—Tolazamide—type 2 diabetes mellitus	0.000226	0.00541	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Bromocriptine—type 2 diabetes mellitus	0.000225	0.00538	CcSEcCtD
Azilsartan medoxomil—Angioedema—Pioglitazone—type 2 diabetes mellitus	0.000224	0.00536	CcSEcCtD
Azilsartan medoxomil—Pruritus—Chlorpropamide—type 2 diabetes mellitus	0.000223	0.00533	CcSEcCtD
Azilsartan medoxomil—Pruritus—Tolazamide—type 2 diabetes mellitus	0.000223	0.00533	CcSEcCtD
Azilsartan medoxomil—Angioedema—Glimepiride—type 2 diabetes mellitus	0.000218	0.00522	CcSEcCtD
Azilsartan medoxomil—Rash—Tolbutamide—type 2 diabetes mellitus	0.000218	0.00522	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Repaglinide—type 2 diabetes mellitus	0.000218	0.00522	CcSEcCtD
Azilsartan medoxomil—Angioedema—Sitagliptin—type 2 diabetes mellitus	0.000218	0.00521	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Chlorpropamide—type 2 diabetes mellitus	0.000215	0.00516	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Linagliptin—type 2 diabetes mellitus	0.000213	0.0051	CcSEcCtD
Azilsartan medoxomil—Asthenia—Nateglinide—type 2 diabetes mellitus	0.000209	0.00501	CcSEcCtD
Azilsartan medoxomil—Dizziness—Chlorpropamide—type 2 diabetes mellitus	0.000208	0.00498	CcSEcCtD
Azilsartan medoxomil—Dizziness—Tolazamide—type 2 diabetes mellitus	0.000208	0.00498	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Pioglitazone—type 2 diabetes mellitus	0.000207	0.00496	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Bromocriptine—type 2 diabetes mellitus	0.000207	0.00496	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Acarbose—type 2 diabetes mellitus	0.000207	0.00495	CcSEcCtD
Azilsartan medoxomil—Pruritus—Nateglinide—type 2 diabetes mellitus	0.000206	0.00494	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Rosiglitazone—type 2 diabetes mellitus	0.000206	0.00493	CcSEcCtD
Azilsartan medoxomil—Fatigue—Rosiglitazone—type 2 diabetes mellitus	0.000206	0.00492	CcSEcCtD
Azilsartan medoxomil—Nausea—Tolbutamide—type 2 diabetes mellitus	0.000206	0.00492	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Losartan—type 2 diabetes mellitus	0.000204	0.00489	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Sitagliptin—type 2 diabetes mellitus	0.000201	0.00482	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Gliclazide—type 2 diabetes mellitus	0.0002	0.00479	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Nateglinide—type 2 diabetes mellitus	0.0002	0.00478	CcSEcCtD
Azilsartan medoxomil—Rash—Tolazamide—type 2 diabetes mellitus	0.000199	0.00475	CcSEcCtD
Azilsartan medoxomil—Rash—Chlorpropamide—type 2 diabetes mellitus	0.000199	0.00475	CcSEcCtD
Azilsartan medoxomil—Rash—Linagliptin—type 2 diabetes mellitus	0.000196	0.0047	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Linagliptin—type 2 diabetes mellitus	0.000196	0.0047	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Pioglitazone—type 2 diabetes mellitus	0.000196	0.0047	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Pioglitazone—type 2 diabetes mellitus	0.000194	0.00465	CcSEcCtD
Azilsartan medoxomil—Dizziness—Nateglinide—type 2 diabetes mellitus	0.000193	0.00462	CcSEcCtD
Azilsartan medoxomil—Rash—Acarbose—type 2 diabetes mellitus	0.000191	0.00457	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Sitagliptin—type 2 diabetes mellitus	0.000191	0.00456	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Acarbose—type 2 diabetes mellitus	0.000191	0.00456	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Sitagliptin—type 2 diabetes mellitus	0.000189	0.00452	CcSEcCtD
Azilsartan medoxomil—Nausea—Tolazamide—type 2 diabetes mellitus	0.000187	0.00448	CcSEcCtD
Azilsartan medoxomil—Nausea—Chlorpropamide—type 2 diabetes mellitus	0.000187	0.00448	CcSEcCtD
Azilsartan medoxomil—Rash—Nateglinide—type 2 diabetes mellitus	0.000184	0.0044	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Nateglinide—type 2 diabetes mellitus	0.000184	0.0044	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Valsartan—type 2 diabetes mellitus	0.000183	0.00439	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Bromocriptine—type 2 diabetes mellitus	0.000182	0.00436	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Orlistat—type 2 diabetes mellitus	0.000182	0.00435	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Glipizide—type 2 diabetes mellitus	0.00018	0.00432	CcSEcCtD
Azilsartan medoxomil—Angioedema—Glyburide—type 2 diabetes mellitus	0.00018	0.00431	CcSEcCtD
Azilsartan medoxomil—Olmesartan—ABCC2—type 2 diabetes mellitus	0.00018	0.0975	CrCbGaD
Azilsartan medoxomil—Nausea—Acarbose—type 2 diabetes mellitus	0.00018	0.0043	CcSEcCtD
Azilsartan medoxomil—Pruritus—Repaglinide—type 2 diabetes mellitus	0.000179	0.00428	CcSEcCtD
Azilsartan medoxomil—Telmisartan—PPARG—type 2 diabetes mellitus	0.000178	0.0964	CrCbGaD
Azilsartan medoxomil—Blood creatinine increased—Ramipril—type 2 diabetes mellitus	0.000175	0.0042	CcSEcCtD
Azilsartan medoxomil—Telmisartan—ABCC2—type 2 diabetes mellitus	0.000173	0.0941	CrCbGaD
Azilsartan medoxomil—Nausea—Nateglinide—type 2 diabetes mellitus	0.000173	0.00415	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Pioglitazone—type 2 diabetes mellitus	0.000173	0.00414	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Repaglinide—type 2 diabetes mellitus	0.000173	0.00413	CcSEcCtD
Azilsartan medoxomil—Fatigue—Pioglitazone—type 2 diabetes mellitus	0.000173	0.00413	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Bromocriptine—type 2 diabetes mellitus	0.000172	0.00413	CcSEcCtD
Azilsartan medoxomil—Asthenia—Rosiglitazone—type 2 diabetes mellitus	0.000171	0.0041	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Bromocriptine—type 2 diabetes mellitus	0.000171	0.00409	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Valsartan—type 2 diabetes mellitus	0.000169	0.00405	CcSEcCtD
Azilsartan medoxomil—Pruritus—Rosiglitazone—type 2 diabetes mellitus	0.000169	0.00404	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Glimepiride—type 2 diabetes mellitus	0.000168	0.00403	CcSEcCtD
Azilsartan medoxomil—Fatigue—Glimepiride—type 2 diabetes mellitus	0.000168	0.00402	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Sitagliptin—type 2 diabetes mellitus	0.000168	0.00402	CcSEcCtD
Azilsartan medoxomil—Fatigue—Sitagliptin—type 2 diabetes mellitus	0.000168	0.00401	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Metformin—type 2 diabetes mellitus	0.000167	0.00401	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Metformin—type 2 diabetes mellitus	0.000167	0.004	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Rosiglitazone—type 2 diabetes mellitus	0.000163	0.00391	CcSEcCtD
Azilsartan medoxomil—Angioedema—Gliclazide—type 2 diabetes mellitus	0.000162	0.00387	CcSEcCtD
Azilsartan medoxomil—Rash—Repaglinide—type 2 diabetes mellitus	0.000159	0.00381	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Repaglinide—type 2 diabetes mellitus	0.000159	0.00381	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Irbesartan—type 2 diabetes mellitus	0.000158	0.00378	CcSEcCtD
Azilsartan medoxomil—Dizziness—Rosiglitazone—type 2 diabetes mellitus	0.000158	0.00378	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Glyburide—type 2 diabetes mellitus	0.000158	0.00377	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Irbesartan—type 2 diabetes mellitus	0.000158	0.00377	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Valsartan—type 2 diabetes mellitus	0.000156	0.00374	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Orlistat—type 2 diabetes mellitus	0.000154	0.0037	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Metformin—type 2 diabetes mellitus	0.000154	0.00369	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Bromocriptine—type 2 diabetes mellitus	0.000152	0.00363	CcSEcCtD
Azilsartan medoxomil—Fatigue—Bromocriptine—type 2 diabetes mellitus	0.000152	0.00363	CcSEcCtD
Azilsartan medoxomil—Rash—Rosiglitazone—type 2 diabetes mellitus	0.00015	0.0036	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	0.00015	0.0036	CcSEcCtD
Azilsartan medoxomil—Nausea—Repaglinide—type 2 diabetes mellitus	0.00015	0.00359	CcSEcCtD
Azilsartan medoxomil—Asthenia—Glipizide—type 2 diabetes mellitus	0.00015	0.00359	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Gliclazide—type 2 diabetes mellitus	0.00015	0.00358	CcSEcCtD
Azilsartan medoxomil—Angioedema—Valsartan—type 2 diabetes mellitus	0.000148	0.00355	CcSEcCtD
Azilsartan medoxomil—Pruritus—Glipizide—type 2 diabetes mellitus	0.000148	0.00354	CcSEcCtD
Azilsartan medoxomil—Angioedema—Orlistat—type 2 diabetes mellitus	0.000147	0.00351	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Irbesartan—type 2 diabetes mellitus	0.000146	0.00348	CcSEcCtD
Azilsartan medoxomil—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.000144	0.00344	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Glipizide—type 2 diabetes mellitus	0.000143	0.00342	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Metformin—type 2 diabetes mellitus	0.000142	0.00341	CcSEcCtD
Azilsartan medoxomil—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.000142	0.00339	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Gliclazide—type 2 diabetes mellitus	0.000142	0.00339	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Gliclazide—type 2 diabetes mellitus	0.00014	0.00336	CcSEcCtD
Azilsartan medoxomil—Asthenia—Glimepiride—type 2 diabetes mellitus	0.00014	0.00335	CcSEcCtD
Azilsartan medoxomil—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.000139	0.00334	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	0.000139	0.00332	CcSEcCtD
Azilsartan medoxomil—Dizziness—Glipizide—type 2 diabetes mellitus	0.000138	0.00331	CcSEcCtD
Azilsartan medoxomil—Pruritus—Glimepiride—type 2 diabetes mellitus	0.000138	0.0033	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Valsartan—type 2 diabetes mellitus	0.000137	0.00329	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Losartan—type 2 diabetes mellitus	0.000137	0.00328	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	0.000137	0.00328	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Orlistat—type 2 diabetes mellitus	0.000136	0.00325	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Irbesartan—type 2 diabetes mellitus	0.000134	0.00321	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.000133	0.00319	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.000133	0.00318	CcSEcCtD
Azilsartan medoxomil—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.000132	0.00317	CcSEcCtD
Azilsartan medoxomil—Rash—Glipizide—type 2 diabetes mellitus	0.000132	0.00315	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Glipizide—type 2 diabetes mellitus	0.000132	0.00315	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.00013	0.00311	CcSEcCtD
Azilsartan medoxomil—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000129	0.00309	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Valsartan—type 2 diabetes mellitus	0.000129	0.00308	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.000129	0.00308	CcSEcCtD
Azilsartan medoxomil—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000128	0.00308	CcSEcCtD
Azilsartan medoxomil—Angioedema—Irbesartan—type 2 diabetes mellitus	0.000128	0.00305	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Ramipril—type 2 diabetes mellitus	0.000128	0.00305	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Orlistat—type 2 diabetes mellitus	0.000127	0.00305	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Ramipril—type 2 diabetes mellitus	0.000127	0.00304	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Losartan—type 2 diabetes mellitus	0.000126	0.00302	CcSEcCtD
Azilsartan medoxomil—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000126	0.00302	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.000125	0.00299	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.000125	0.00298	CcSEcCtD
Azilsartan medoxomil—Fatigue—Gliclazide—type 2 diabetes mellitus	0.000124	0.00298	CcSEcCtD
Azilsartan medoxomil—Nausea—Glipizide—type 2 diabetes mellitus	0.000124	0.00297	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CCKAR—type 2 diabetes mellitus	0.000124	0.00707	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Arf6 signaling events—SRC—type 2 diabetes mellitus	0.000123	0.00702	CbGpPWpGaD
Azilsartan medoxomil—Rash—Glimepiride—type 2 diabetes mellitus	0.000123	0.00294	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000123	0.00294	CcSEcCtD
Azilsartan medoxomil—Rash—Sitagliptin—type 2 diabetes mellitus	0.000123	0.00293	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000122	0.00293	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.00012	0.00288	CcSEcCtD
Azilsartan medoxomil—Angioedema—Losartan—type 2 diabetes mellitus	0.00012	0.00287	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—MC4R—type 2 diabetes mellitus	0.00012	0.00684	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000118	0.00283	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000118	0.00283	CcSEcCtD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—RELA—type 2 diabetes mellitus	0.000118	0.00672	CbGpPWpGaD
Azilsartan medoxomil—Skin disorder—Metformin—type 2 diabetes mellitus	0.000117	0.00281	CcSEcCtD
Azilsartan medoxomil—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000116	0.00278	CcSEcCtD
Azilsartan medoxomil—Nausea—Glimepiride—type 2 diabetes mellitus	0.000116	0.00277	CcSEcCtD
Azilsartan medoxomil—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000115	0.00276	CcSEcCtD
Azilsartan medoxomil—Asthenia—Glyburide—type 2 diabetes mellitus	0.000115	0.00276	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000114	0.00274	CcSEcCtD
Azilsartan medoxomil—Fatigue—Valsartan—type 2 diabetes mellitus	0.000114	0.00274	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—ADRB3—type 2 diabetes mellitus	0.000114	0.00653	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Glyburide—type 2 diabetes mellitus	0.000114	0.00272	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.000113	0.00271	CcSEcCtD
Azilsartan medoxomil—Fatigue—Orlistat—type 2 diabetes mellitus	0.000113	0.0027	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—CCKAR—type 2 diabetes mellitus	0.000112	0.0064	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000112	0.00268	CcSEcCtD
Azilsartan medoxomil—Rash—Bromocriptine—type 2 diabetes mellitus	0.000111	0.00265	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000111	0.00265	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000111	0.00265	CcSEcCtD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—TRPC6—type 2 diabetes mellitus	0.00011	0.00629	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.00011	0.00263	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Ramipril—type 2 diabetes mellitus	0.000108	0.00259	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—GCGR—type 2 diabetes mellitus	0.000108	0.00619	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—AGTR2—type 2 diabetes mellitus	0.000108	0.00618	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Arf6 signaling events—EGFR—type 2 diabetes mellitus	0.000108	0.00616	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.000105	0.00252	CcSEcCtD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—EDNRB—type 2 diabetes mellitus	0.000105	0.00599	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000104	0.0025	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.000104	0.0025	CcSEcCtD
Azilsartan medoxomil—Fatigue—Metformin—type 2 diabetes mellitus	0.000104	0.00249	CcSEcCtD
Azilsartan medoxomil—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000104	0.00248	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—EDNRB—type 2 diabetes mellitus	0.000104	0.00592	CbGpPWpGaD
Azilsartan medoxomil—Angioedema—Ramipril—type 2 diabetes mellitus	0.000103	0.00246	CcSEcCtD
Azilsartan medoxomil—Pruritus—Gliclazide—type 2 diabetes mellitus	0.000102	0.00244	CcSEcCtD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—HTR2C—type 2 diabetes mellitus	0.000102	0.00582	CbGpPWpGaD
Azilsartan medoxomil—Rash—Glyburide—type 2 diabetes mellitus	0.000101	0.00243	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000101	0.00242	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—MTNR1B—type 2 diabetes mellitus	0.000101	0.00577	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—GIPR—type 2 diabetes mellitus	9.96e-05	0.00569	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—NFKB1—type 2 diabetes mellitus	9.92e-05	0.00567	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—EDNRA—type 2 diabetes mellitus	9.9e-05	0.00566	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Gliclazide—type 2 diabetes mellitus	9.88e-05	0.00236	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—TRPC6—type 2 diabetes mellitus	9.85e-05	0.00563	CbGpPWpGaD
Azilsartan medoxomil—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	9.84e-05	0.00236	CcSEcCtD
Azilsartan medoxomil—Fatigue—Irbesartan—type 2 diabetes mellitus	9.83e-05	0.00235	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—ADRB3—type 2 diabetes mellitus	9.8e-05	0.0056	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—EDNRA—type 2 diabetes mellitus	9.78e-05	0.00559	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CASP8—type 2 diabetes mellitus	9.72e-05	0.00556	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—CCKAR—type 2 diabetes mellitus	9.68e-05	0.00553	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—GHRL—type 2 diabetes mellitus	9.65e-05	0.00551	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Glyburide—type 2 diabetes mellitus	9.55e-05	0.00229	CcSEcCtD
Azilsartan medoxomil—Dizziness—Gliclazide—type 2 diabetes mellitus	9.55e-05	0.00228	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	9.53e-05	0.00228	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—GHRL—type 2 diabetes mellitus	9.53e-05	0.00544	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Valsartan—type 2 diabetes mellitus	9.52e-05	0.00228	CcSEcCtD
Azilsartan medoxomil—Asthenia—Orlistat—type 2 diabetes mellitus	9.4e-05	0.00225	CcSEcCtD
Azilsartan medoxomil—Tasosartan—CYP3A4—type 2 diabetes mellitus	9.4e-05	0.051	CrCbGaD
Azilsartan medoxomil—Pruritus—Valsartan—type 2 diabetes mellitus	9.38e-05	0.00225	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EDNRB—type 2 diabetes mellitus	9.38e-05	0.00536	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Orlistat—type 2 diabetes mellitus	9.27e-05	0.00222	CcSEcCtD
Azilsartan medoxomil—Fatigue—Losartan—type 2 diabetes mellitus	9.25e-05	0.00221	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—MC4R—type 2 diabetes mellitus	9.11e-05	0.00521	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2C—type 2 diabetes mellitus	9.1e-05	0.0052	CbGpPWpGaD
Azilsartan medoxomil—Rash—Gliclazide—type 2 diabetes mellitus	9.1e-05	0.00218	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Gliclazide—type 2 diabetes mellitus	9.09e-05	0.00218	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Valsartan—type 2 diabetes mellitus	9.07e-05	0.00217	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Ramipril—type 2 diabetes mellitus	9.02e-05	0.00216	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Orlistat—type 2 diabetes mellitus	8.97e-05	0.00215	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Ramipril—type 2 diabetes mellitus	8.93e-05	0.00214	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EDNRA—type 2 diabetes mellitus	8.86e-05	0.00506	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—GCG—type 2 diabetes mellitus	8.83e-05	0.00504	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—GIP—type 2 diabetes mellitus	8.77e-05	0.00501	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Valsartan—type 2 diabetes mellitus	8.77e-05	0.0021	CcSEcCtD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—RASGRP1—type 2 diabetes mellitus	8.68e-05	0.00496	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Orlistat—type 2 diabetes mellitus	8.67e-05	0.00207	CcSEcCtD
Azilsartan medoxomil—Asthenia—Metformin—type 2 diabetes mellitus	8.66e-05	0.00207	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—MTNR1B—type 2 diabetes mellitus	8.65e-05	0.00494	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—type 2 diabetes mellitus	8.63e-05	0.00493	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Gliclazide—type 2 diabetes mellitus	8.57e-05	0.00205	CcSEcCtD
Azilsartan medoxomil—Pruritus—Metformin—type 2 diabetes mellitus	8.54e-05	0.00205	CcSEcCtD
Azilsartan medoxomil—Losartan—ACE—type 2 diabetes mellitus	8.47e-05	0.046	CrCbGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—AGTR2—type 2 diabetes mellitus	8.46e-05	0.00484	CbGpPWpGaD
Azilsartan medoxomil—Rash—Valsartan—type 2 diabetes mellitus	8.36e-05	0.002	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Valsartan—type 2 diabetes mellitus	8.35e-05	0.002	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCKAR—type 2 diabetes mellitus	8.3e-05	0.00474	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Metformin—type 2 diabetes mellitus	8.26e-05	0.00198	CcSEcCtD
Azilsartan medoxomil—Rash—Orlistat—type 2 diabetes mellitus	8.26e-05	0.00198	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Orlistat—type 2 diabetes mellitus	8.25e-05	0.00198	CcSEcCtD
Azilsartan medoxomil—Asthenia—Irbesartan—type 2 diabetes mellitus	8.18e-05	0.00196	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—EDNRB—type 2 diabetes mellitus	8.1e-05	0.00463	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Irbesartan—type 2 diabetes mellitus	8.06e-05	0.00193	CcSEcCtD
Azilsartan medoxomil—Dizziness—Metformin—type 2 diabetes mellitus	7.99e-05	0.00191	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	7.94e-05	0.0019	CcSEcCtD
Azilsartan medoxomil—Fatigue—Ramipril—type 2 diabetes mellitus	7.93e-05	0.0019	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GCG—type 2 diabetes mellitus	7.89e-05	0.00451	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Valsartan—type 2 diabetes mellitus	7.88e-05	0.00189	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—HTR2C—type 2 diabetes mellitus	7.87e-05	0.0045	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Irbesartan—type 2 diabetes mellitus	7.8e-05	0.00187	CcSEcCtD
Azilsartan medoxomil—Nausea—Orlistat—type 2 diabetes mellitus	7.78e-05	0.00186	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—RASGRP1—type 2 diabetes mellitus	7.77e-05	0.00444	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—type 2 diabetes mellitus	7.71e-05	0.00441	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Losartan—type 2 diabetes mellitus	7.7e-05	0.00184	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—EDNRA—type 2 diabetes mellitus	7.65e-05	0.00437	CbGpPWpGaD
Azilsartan medoxomil—Rash—Metformin—type 2 diabetes mellitus	7.61e-05	0.00182	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Metformin—type 2 diabetes mellitus	7.61e-05	0.00182	CcSEcCtD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—GNB3—type 2 diabetes mellitus	7.61e-05	0.00435	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Losartan—type 2 diabetes mellitus	7.59e-05	0.00182	CcSEcCtD
Azilsartan medoxomil—Dizziness—Irbesartan—type 2 diabetes mellitus	7.54e-05	0.0018	CcSEcCtD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—AVP—type 2 diabetes mellitus	7.5e-05	0.00429	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—ADRA2A—type 2 diabetes mellitus	7.49e-05	0.00428	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—ADRB3—type 2 diabetes mellitus	7.46e-05	0.00426	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—AVP—type 2 diabetes mellitus	7.41e-05	0.00423	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CASP3—type 2 diabetes mellitus	7.36e-05	0.0042	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Losartan—type 2 diabetes mellitus	7.34e-05	0.00176	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—AGTR2—type 2 diabetes mellitus	7.25e-05	0.00414	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CRHR1—type 2 diabetes mellitus	7.2e-05	0.00412	CbGpPWpGaD
Azilsartan medoxomil—Rash—Irbesartan—type 2 diabetes mellitus	7.19e-05	0.00172	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Irbesartan—type 2 diabetes mellitus	7.18e-05	0.00172	CcSEcCtD
Azilsartan medoxomil—Nausea—Metformin—type 2 diabetes mellitus	7.17e-05	0.00172	CcSEcCtD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—EDN1—type 2 diabetes mellitus	7.14e-05	0.00408	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Losartan—type 2 diabetes mellitus	7.09e-05	0.0017	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—MTNR1A—type 2 diabetes mellitus	7.09e-05	0.00405	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—EDN1—type 2 diabetes mellitus	7.05e-05	0.00403	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—EDNRB—type 2 diabetes mellitus	6.94e-05	0.00397	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GNB3—type 2 diabetes mellitus	6.8e-05	0.00389	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Irbesartan—type 2 diabetes mellitus	6.77e-05	0.00162	CcSEcCtD
Azilsartan medoxomil—Rash—Losartan—type 2 diabetes mellitus	6.76e-05	0.00162	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Losartan—type 2 diabetes mellitus	6.76e-05	0.00162	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—HTR2C—type 2 diabetes mellitus	6.74e-05	0.00385	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—type 2 diabetes mellitus	6.71e-05	0.00384	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—type 2 diabetes mellitus	6.71e-05	0.00384	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Ramipril—type 2 diabetes mellitus	6.6e-05	0.00158	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—MTNR1B—type 2 diabetes mellitus	6.59e-05	0.00377	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—EDNRA—type 2 diabetes mellitus	6.56e-05	0.00375	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Ramipril—type 2 diabetes mellitus	6.51e-05	0.00156	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—MTNR1A—type 2 diabetes mellitus	6.44e-05	0.00368	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—GLP1R—type 2 diabetes mellitus	6.42e-05	0.00367	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—type 2 diabetes mellitus	6.42e-05	0.00367	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—GHRL—type 2 diabetes mellitus	6.39e-05	0.00365	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—type 2 diabetes mellitus	6.38e-05	0.00365	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Losartan—type 2 diabetes mellitus	6.37e-05	0.00152	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CCKAR—type 2 diabetes mellitus	6.32e-05	0.00361	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CCR5—type 2 diabetes mellitus	6.3e-05	0.0036	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Ramipril—type 2 diabetes mellitus	6.29e-05	0.00151	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—VEGFA—type 2 diabetes mellitus	6.24e-05	0.00357	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—C3—type 2 diabetes mellitus	6.16e-05	0.00352	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—GCGR—type 2 diabetes mellitus	6.12e-05	0.0035	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Ramipril—type 2 diabetes mellitus	6.08e-05	0.00146	CcSEcCtD
Azilsartan medoxomil—Losartan—CYP1A2—type 2 diabetes mellitus	6.01e-05	0.0326	CrCbGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—AGT—type 2 diabetes mellitus	5.92e-05	0.00339	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—AGT—type 2 diabetes mellitus	5.85e-05	0.00334	CbGpPWpGaD
Azilsartan medoxomil—Rash—Ramipril—type 2 diabetes mellitus	5.8e-05	0.00139	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Ramipril—type 2 diabetes mellitus	5.79e-05	0.00139	CcSEcCtD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—AKT1—type 2 diabetes mellitus	5.74e-05	0.00328	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—TGFB1—type 2 diabetes mellitus	5.73e-05	0.00327	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—IAPP—type 2 diabetes mellitus	5.69e-05	0.00325	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—GRK5—type 2 diabetes mellitus	5.63e-05	0.00322	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—GIPR—type 2 diabetes mellitus	5.63e-05	0.00322	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—GCGR—type 2 diabetes mellitus	5.56e-05	0.00318	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—AGTR2—type 2 diabetes mellitus	5.52e-05	0.00316	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Ramipril—type 2 diabetes mellitus	5.46e-05	0.00131	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—TNF—type 2 diabetes mellitus	5.35e-05	0.00306	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—type 2 diabetes mellitus	5.3e-05	0.00303	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—EDNRB—type 2 diabetes mellitus	5.29e-05	0.00302	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ARAP1—type 2 diabetes mellitus	5.26e-05	0.00301	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—MC4R—type 2 diabetes mellitus	5.15e-05	0.00294	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—HTR2C—type 2 diabetes mellitus	5.13e-05	0.00293	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—GIPR—type 2 diabetes mellitus	5.11e-05	0.00292	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—GRK5—type 2 diabetes mellitus	5.11e-05	0.00292	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—EDNRA—type 2 diabetes mellitus	4.99e-05	0.00285	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—AVP—type 2 diabetes mellitus	4.97e-05	0.00284	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—GIP—type 2 diabetes mellitus	4.96e-05	0.00283	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—CCR5—type 2 diabetes mellitus	4.93e-05	0.00282	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—ADRA2A—type 2 diabetes mellitus	4.89e-05	0.00279	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—GHRL—type 2 diabetes mellitus	4.87e-05	0.00278	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CCL2—type 2 diabetes mellitus	4.82e-05	0.00275	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—VPS26A—type 2 diabetes mellitus	4.81e-05	0.00275	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CALCA—type 2 diabetes mellitus	4.81e-05	0.00275	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—EDN1—type 2 diabetes mellitus	4.73e-05	0.0027	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—MC4R—type 2 diabetes mellitus	4.68e-05	0.00267	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—GIP—type 2 diabetes mellitus	4.5e-05	0.00257	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—GCG—type 2 diabetes mellitus	4.45e-05	0.00254	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—PIK3R1—type 2 diabetes mellitus	4.35e-05	0.00249	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR5—type 2 diabetes mellitus	4.23e-05	0.00241	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—ADRB3—type 2 diabetes mellitus	4.22e-05	0.00241	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—C3—type 2 diabetes mellitus	4.13e-05	0.00236	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CRHR1—type 2 diabetes mellitus	4.07e-05	0.00233	CbGpPWpGaD
Azilsartan medoxomil—Losartan—CYP3A4—type 2 diabetes mellitus	3.98e-05	0.0216	CrCbGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—AGT—type 2 diabetes mellitus	3.92e-05	0.00224	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3R1—type 2 diabetes mellitus	3.89e-05	0.00222	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—GNB3—type 2 diabetes mellitus	3.84e-05	0.00219	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—ADRB3—type 2 diabetes mellitus	3.83e-05	0.00219	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MTNR1A—type 2 diabetes mellitus	3.8e-05	0.00217	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—AVP—type 2 diabetes mellitus	3.78e-05	0.00216	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—MTNR1B—type 2 diabetes mellitus	3.72e-05	0.00213	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CRHR1—type 2 diabetes mellitus	3.7e-05	0.00211	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—GLP1R—type 2 diabetes mellitus	3.63e-05	0.00207	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—EDN1—type 2 diabetes mellitus	3.6e-05	0.00206	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CCKAR—type 2 diabetes mellitus	3.57e-05	0.00204	CbGpPWpGaD
Azilsartan medoxomil—Losartan—ALB—type 2 diabetes mellitus	3.47e-05	0.0188	CrCbGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—MTNR1B—type 2 diabetes mellitus	3.38e-05	0.00193	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—GLP1R—type 2 diabetes mellitus	3.3e-05	0.00188	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GCGR—type 2 diabetes mellitus	3.28e-05	0.00188	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCKAR—type 2 diabetes mellitus	3.24e-05	0.00185	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL2—type 2 diabetes mellitus	3.23e-05	0.00185	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CCR5—type 2 diabetes mellitus	3.22e-05	0.00184	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—IAPP—type 2 diabetes mellitus	3.21e-05	0.00184	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—C3—type 2 diabetes mellitus	3.14e-05	0.0018	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—TRPC6—type 2 diabetes mellitus	3.14e-05	0.00179	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—AGTR2—type 2 diabetes mellitus	3.12e-05	0.00178	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GIPR—type 2 diabetes mellitus	3.02e-05	0.00173	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GRK5—type 2 diabetes mellitus	3.02e-05	0.00173	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—EDNRB—type 2 diabetes mellitus	2.99e-05	0.00171	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—AGT—type 2 diabetes mellitus	2.99e-05	0.00171	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IAPP—type 2 diabetes mellitus	2.92e-05	0.00167	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—HTR2C—type 2 diabetes mellitus	2.9e-05	0.00166	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—TRPC6—type 2 diabetes mellitus	2.85e-05	0.00163	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—AGTR2—type 2 diabetes mellitus	2.83e-05	0.00162	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—EDNRA—type 2 diabetes mellitus	2.82e-05	0.00161	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MC4R—type 2 diabetes mellitus	2.76e-05	0.00158	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—ADRA2A—type 2 diabetes mellitus	2.76e-05	0.00158	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—GHRL—type 2 diabetes mellitus	2.75e-05	0.00157	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CALCA—type 2 diabetes mellitus	2.72e-05	0.00155	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—EDNRB—type 2 diabetes mellitus	2.71e-05	0.00155	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GIP—type 2 diabetes mellitus	2.66e-05	0.00152	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—HTR2C—type 2 diabetes mellitus	2.63e-05	0.00151	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—EDNRA—type 2 diabetes mellitus	2.56e-05	0.00146	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—LEPR—type 2 diabetes mellitus	2.53e-05	0.00144	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—type 2 diabetes mellitus	2.52e-05	0.00144	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—GCG—type 2 diabetes mellitus	2.52e-05	0.00144	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—ADRA2A—type 2 diabetes mellitus	2.51e-05	0.00143	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—GHRL—type 2 diabetes mellitus	2.5e-05	0.00143	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—RASGRP1—type 2 diabetes mellitus	2.47e-05	0.00141	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CALCA—type 2 diabetes mellitus	2.47e-05	0.00141	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CCL2—type 2 diabetes mellitus	2.46e-05	0.00141	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ATP2A3—type 2 diabetes mellitus	2.41e-05	0.00138	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TLE4—type 2 diabetes mellitus	2.35e-05	0.00134	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—GCG—type 2 diabetes mellitus	2.28e-05	0.00131	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ADRB3—type 2 diabetes mellitus	2.26e-05	0.00129	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—RASGRP1—type 2 diabetes mellitus	2.25e-05	0.00128	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CRHR1—type 2 diabetes mellitus	2.18e-05	0.00125	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—GNB3—type 2 diabetes mellitus	2.17e-05	0.00124	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—AVP—type 2 diabetes mellitus	2.14e-05	0.00122	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—EDN1—type 2 diabetes mellitus	2.03e-05	0.00116	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PRKAA1—type 2 diabetes mellitus	2.02e-05	0.00115	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MTNR1B—type 2 diabetes mellitus	2e-05	0.00114	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SPRY2—type 2 diabetes mellitus	2e-05	0.00114	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—GNB3—type 2 diabetes mellitus	1.97e-05	0.00113	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—RBP4—type 2 diabetes mellitus	1.95e-05	0.00111	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GLP1R—type 2 diabetes mellitus	1.95e-05	0.00111	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—MMP3—type 2 diabetes mellitus	1.94e-05	0.00111	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—AVP—type 2 diabetes mellitus	1.94e-05	0.00111	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—type 2 diabetes mellitus	1.94e-05	0.00111	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—ADCY5—type 2 diabetes mellitus	1.93e-05	0.0011	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCKAR—type 2 diabetes mellitus	1.92e-05	0.00109	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—EDN1—type 2 diabetes mellitus	1.85e-05	0.00106	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CCR5—type 2 diabetes mellitus	1.82e-05	0.00104	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—C3—type 2 diabetes mellitus	1.78e-05	0.00102	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—ADCY5—type 2 diabetes mellitus	1.75e-05	0.001	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	1.74e-05	0.000992	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IAPP—type 2 diabetes mellitus	1.72e-05	0.000985	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—INSR—type 2 diabetes mellitus	1.71e-05	0.000979	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—AGT—type 2 diabetes mellitus	1.69e-05	0.000965	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TRPC6—type 2 diabetes mellitus	1.68e-05	0.000962	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	1.68e-05	0.000961	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—AGTR2—type 2 diabetes mellitus	1.67e-05	0.000957	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCR5—type 2 diabetes mellitus	1.65e-05	0.000944	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—C3—type 2 diabetes mellitus	1.61e-05	0.000922	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—EDNRB—type 2 diabetes mellitus	1.6e-05	0.000916	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	1.56e-05	0.000892	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PSMD6—type 2 diabetes mellitus	1.56e-05	0.000889	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HTR2C—type 2 diabetes mellitus	1.56e-05	0.000889	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—AGT—type 2 diabetes mellitus	1.53e-05	0.000876	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—EDNRA—type 2 diabetes mellitus	1.51e-05	0.000865	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CALM1—type 2 diabetes mellitus	1.51e-05	0.000862	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CYBA—type 2 diabetes mellitus	1.51e-05	0.000861	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	1.48e-05	0.000847	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PLAT—type 2 diabetes mellitus	1.48e-05	0.000843	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GHRL—type 2 diabetes mellitus	1.48e-05	0.000843	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CALCA—type 2 diabetes mellitus	1.46e-05	0.000833	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	1.42e-05	0.00081	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.37e-05	0.000784	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.37e-05	0.000781	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GCG—type 2 diabetes mellitus	1.35e-05	0.000771	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.35e-05	0.000771	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.33e-05	0.000759	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.32e-05	0.000756	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCL2—type 2 diabetes mellitus	1.26e-05	0.000722	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—AKT2—type 2 diabetes mellitus	1.24e-05	0.000709	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	1.24e-05	0.000708	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.17e-05	0.000671	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.16e-05	0.000665	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.15e-05	0.000656	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—AVP—type 2 diabetes mellitus	1.15e-05	0.000656	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.14e-05	0.000653	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.14e-05	0.00065	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.13e-05	0.000643	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—APOB—type 2 diabetes mellitus	1.11e-05	0.000634	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.1e-05	0.000631	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.09e-05	0.000624	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—LPL—type 2 diabetes mellitus	1.06e-05	0.000605	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.04e-05	0.000592	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	9.93e-06	0.000568	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCR5—type 2 diabetes mellitus	9.76e-06	0.000557	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—C3—type 2 diabetes mellitus	9.53e-06	0.000545	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	9.09e-06	0.00052	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IRS2—type 2 diabetes mellitus	9.07e-06	0.000518	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—AGT—type 2 diabetes mellitus	9.06e-06	0.000518	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CALM1—type 2 diabetes mellitus	8.91e-06	0.000509	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—LEP—type 2 diabetes mellitus	8.87e-06	0.000507	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—APOE—type 2 diabetes mellitus	8.87e-06	0.000507	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—APOA1—type 2 diabetes mellitus	8.77e-06	0.000501	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	8.37e-06	0.000478	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IRS1—type 2 diabetes mellitus	7.92e-06	0.000452	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—INS—type 2 diabetes mellitus	7.58e-06	0.000433	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCL2—type 2 diabetes mellitus	7.46e-06	0.000426	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IGF1—type 2 diabetes mellitus	7.33e-06	0.000419	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—AKT2—type 2 diabetes mellitus	7.33e-06	0.000419	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	7.3e-06	0.000417	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	6.96e-06	0.000398	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	6.65e-06	0.00038	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NOS3—type 2 diabetes mellitus	6.65e-06	0.00038	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—RELA—type 2 diabetes mellitus	6.26e-06	0.000358	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.7e-06	0.000326	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.64e-06	0.000323	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.61e-06	0.00032	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.33e-06	0.000305	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.28e-06	0.000302	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	5.17e-06	0.000296	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SRC—type 2 diabetes mellitus	4.92e-06	0.000281	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.79e-06	0.000274	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.4e-06	0.000251	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.31e-06	0.000246	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IL6—type 2 diabetes mellitus	3.31e-06	0.000189	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.06e-06	0.000175	CbGpPWpGaD
